Literature DB >> 27735004

Structural essentials for β-N-acetylhexosaminidase inhibition by amides of prolines, pipecolic and azetidine carboxylic acids.

A F G Glawar1, R F Martínez2, B J Ayers2, M A Hollas2, N Ngo2, S Nakagawa3, A Kato3, T D Butters4, G W J Fleet1, S F Jenkinson2.   

Abstract

This paper explores the computer modelling aided design and synthesis of β-N-acetylhexosaminidase inhibitors along with their applicability to human disease treatment through biological evaluation in both an enzymatic and cellular setting. We investigated the importance of individual stereocenters, variations in structure-activity relationships along with factors influencing cell penetration. To achieve these goals we modified nitrogen heterocycles in terms of ring size, side chains present and ring nitrogen derivatization. By reducing the inhibitor interactions with the active site down to the essentials we were able to determine that besides the established 2S,3R trans-relationship, the presence and stereochemistry of the CH2OH side chain is of crucial importance for activity. In terms of cellular penetration, N-butyl side chains favour cellar uptake, while hydroxy- and carboxy-group bearing sidechains on the ring nitrogen retarded cellular penetration. Furthermore we show an early proof of principle study that β-N-acetylhexosaminidase inhibitors can be applicable to use in a potential anti-invasive anti-cancer strategy.

Entities:  

Year:  2016        PMID: 27735004     DOI: 10.1039/c6ob01549b

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  7 in total

1.  Borylated 2,3,4,5-Tetrachlorophthalimide and Their 2,3,4,5-Tetrachlorobenzamide Analogues: Synthesis, Their Glycosidase Inhibition and Anticancer Properties in View to Boron Neutron Capture Therapy.

Authors:  David M Campkin; Yuna Shimadate; Barbara Bartholomew; Paul V Bernhardt; Robert J Nash; Jennette A Sakoff; Atsushi Kato; Michela I Simone
Journal:  Molecules       Date:  2022-05-26       Impact factor: 4.927

2.  sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease.

Authors:  Manuel González-Cuesta; Irene Herrera-González; M Isabel García-Moreno; Roger A Ashmus; David J Vocadlo; José M García Fernández; Eiji Nanba; Katsumi Higaki; Carmen Ortiz Mellet
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

3.  shRNA-mediated downregulation of α-N-Acetylgalactosaminidase inhibits migration and invasion of cancer cell lines.

Authors:  Ehsan Saburi; Jalil Tavakolafshari; Yousef Mortazavi; Alireza Biglari; Seyed Abbas Mirzaei; Samad Nadri
Journal:  Iran J Basic Med Sci       Date:  2017-09       Impact factor: 2.699

4.  Combined Enzyme- and Transition Metal-Catalyzed Strategy for the Enantioselective Syntheses of Nitrogen Heterocycles: (-)-Coniine, DAB-1, and Nectrisine.

Authors:  Donald R Deardorff; Scott W Niman; Mark I Paulsen; Anasheh Sookezian; Meghan E Whalen; Christopher J Finlayson; Collrane Frivold; Hilary C Brown; Jeffrey S Cannon
Journal:  ACS Omega       Date:  2020-01-23

5.  Practical one-pot amidation of N-Alloc-, N-Boc-, and N-Cbz protected amines under mild conditions.

Authors:  Wan Pyo Hong; Van Hieu Tran; Hee-Kwon Kim
Journal:  RSC Adv       Date:  2021-04-28       Impact factor: 3.361

6.  Potent GH20 N-Acetyl-β-d-hexosaminidase Inhibitors: N-Substituted 3-acetamido-4-amino-5-hydroxymethyl-cyclopentanediols.

Authors:  Patrick Weber; Seyed A Nasseri; Bettina M Pabst; Ana Torvisco; Philipp Müller; Eduard Paschke; Marion Tschernutter; Werner Windischhofer; Stephen G Withers; Tanja M Wrodnigg; Arnold E Stütz
Journal:  Molecules       Date:  2018-03-20       Impact factor: 4.411

7.  Synthesis of Pyrrolidine Monocyclic Analogues of Pochonicine and Its Stereoisomers: Pursuit ofSimplified Structures and Potent β-N-Acetylhexosaminidase Inhibition.

Authors:  Xin Yan; Yuna Shimadate; Atsushi Kato; Yi-Xian Li; Yue-Mei Jia; George W J Fleet; Chu-Yi Yu
Journal:  Molecules       Date:  2020-03-25       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.